HER2-Based Immunotherapy for Breast Cancer-Reference-Cited by-同舟云学术

HER2-Based Immunotherapy for Breast Cancer

Published:2018-06 Issue:5 Volume:33 Page:169-175
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Cui Naipeng¹,Shi Jianhong²,Yang Chuanwei³

Affiliation:

1. Department of Breast Surgery, Affiliated Hospital of Hebei University, Baoding, China.

2. Central Laboratory, Hebei Laboratory of Mechanism and Procedure of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, Baoding, China.

3. Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2017.2327

Reference73 articles.

1. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

4. The Role of the Cyclin D1-Dependent Kinases in ErbB2-Mediated Breast Cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylactic Vaccination and Intratumoral Boost with HER2-Expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response against HER2-Positive Tumor Cells;Vaccines;2023-12-02

2. Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer;Cancers;2022-11-18

3. Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches;Journal of Controlled Release;2022-09

4. Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model;Journal of Cancer Research and Clinical Oncology;2022-06-23

5. Vaccination against Her-2/neu, with focus on peptide-based vaccines;ESMO Open;2022-02